Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors.

Item

http://www.wikidata.org/entity/Q42319246

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Association Between Tumor Prog ...... dvanced Neuroendocrine Tumors.

@en

Association Between Tumor Prog ...... dvanced Neuroendocrine Tumors.

@nl

type

Item

label

Association Between Tumor Prog ...... dvanced Neuroendocrine Tumors.

@en

Association Between Tumor Prog ...... dvanced Neuroendocrine Tumors.

@nl

prefLabel

Association Between Tumor Prog ...... dvanced Neuroendocrine Tumors.

@en

Association Between Tumor Prog ...... dvanced Neuroendocrine Tumors.

@nl

P1476

Association Between Tumor Prog ...... dvanced Neuroendocrine Tumors.

@en

P2093

David C Christiani

http://www.w3.org/2001/XMLSchema#string

Jennifer A Chan

http://www.w3.org/2001/XMLSchema#string

Jérôme Dinet

http://www.w3.org/2001/XMLSchema#string

Lauren K Brais

http://www.w3.org/2001/XMLSchema#string

Matthew H Kulke

http://www.w3.org/2001/XMLSchema#string

Nichole V Brooks

http://www.w3.org/2001/XMLSchema#string

Sui Zhang

http://www.w3.org/2001/XMLSchema#string

Sylvie Gabriel

http://www.w3.org/2001/XMLSchema#string

Xihong Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Detecting an overall survival benefit that is derived from progression-free survival

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.

P304

165-172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2016-0175

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Monica Ter-Minassian

P577

2017-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28179574

http://www.w3.org/2001/XMLSchema#string

P932

5330705

http://www.w3.org/2001/XMLSchema#string